



LUGPA

Integrated Practices
Comprehensive Care

2026 LUGPA

Global Prostate Cancer Congress

JANUARY 10–13, 2026

The Grand Hyatt Deer Valley | Park City, Utah

lugpa.org    

LUGPA 2026 Global Prostate Cancer Congress

January 10 – 13
The Grand Hyatt Deer Valley
Park City, UT



Table of Contents

- 3 Welcome Letter**
- 4 Educational Needs/Learning Objectives**
- 5 List of Speakers**
- 6 Accreditation and Designation Statements,
and Disclosure Report**
- 10 Program Agenda**
- 18 How to Obtain Your CME Certificate**
- 19 Industry Sponsored Symposia**
- 20 Floor Plan**
- 21 Sponsors**
- 22 Faculty Biographies**
- 27 Upcoming LUGPA Events**

Officers

President

Scott B. Sellinger, MD
Tallahassee, FL

President-Elect

Jeffrey Spier, MD
El Paso, TX

Secretary

Benjamin H. Lowentritt, MD
Baltimore, MD

Treasurer

Kirsten Anderson, CMPE,
CPC, CASC
Myrtle Beach, SC

Past President

Evan Goldfischer, MD, MBA
Poughkeepsie, NY

Board of Directors

Gordon Brown, DO, FACOS
Sewell, NJ

Benjamin Coons, MD
Colorado Springs, CO

Nathan Diller, MBA, MHSA, FACHE, CMPE
Wilmington, DE

Erika Ferrozzo, MHA
Meridian, ID

Jason Hafron, MD
Troy, MI

Vahan Kassabian, MD,
FACS, FRCS (C)
Atlanta, GA

David Morris, MD
Nashville, TN

Timothy Richardson, MD
Wichita, KS

Chief Executive Officer

Celeste G. Kirschner, CAE, MHA
Chicago, IL

875 N. Michigan Avenue
Suite 3100
Chicago, IL 60611
www.lugpa.org



Welcome



On behalf of the LUGPA Board of Directors, welcome to the 2026 Global Prostate Cancer Congress at the Grand Hyatt Deer Valley in beautiful Park City, Utah. We are delighted to gather once again with an exceptional, world-renowned faculty who will guide us through today's most critical and rapidly evolving topics in prostate cancer care—from precision diagnostics and molecular imaging to treatment sequencing, genomics, theranostics, and survivorship.

This year's program was intentionally designed around the most pressing educational needs facing clinicians across the prostate cancer continuum. As treatments, technologies, and guidelines evolve, clinicians must integrate multidisciplinary models of care, interpret increasingly complex diagnostic tools, and personalize treatment strategies for localized, hormone-sensitive, and castration-resistant disease. Equally important is the need to navigate policy and reimbursement challenges, manage ADT-related effects, and engage patients and caregivers in shared, holistic decision-making that supports long-term quality of life.

Across three days, the agenda provides evidence-based updates, expert debates, case discussions, and collaborative panels addressing today's most relevant clinical and scientific questions. Sessions highlight advances in imaging—including PSMA PET, MRI, and novel tracers—emerging biomarkers, genomic interpretation, AI-driven precision medicine, evolving surgical and radiation techniques, treatment intensification strategies, and next-line therapies for CRPC. We also continue our focus on APP-directed care models, caregiver perspectives, survivorship, and the policy landscape shaping patient access and innovation. Industry-sponsored symposia, scheduled breaks, and evening events offer valuable opportunities to network with peers, explore new technologies, and engage with our partners.

I extend my heartfelt gratitude to our Program Chair, Dr. E. David Crawford, our Co-Chair, Dr. David Morris, and the outstanding faculty who have dedicated their time and expertise to building such a comprehensive and forward-looking program. I also wish to thank our sponsors and our Specialty Networks colleagues for their support, as well as the entire LUGPA staff for their exceptional work in producing this meeting.

Thank you for joining us and for your commitment to advancing excellence in prostate cancer care. We hope you enjoy the sessions, the learning, the collaboration—and the beauty of Park City in winter. We look forward to continuing to grow the Global Prostate Cancer Congress with you in the years ahead.

Sincerely,

Scott B. Sellinger, MD
President, LUGPA

Educational Needs

Clinicians across the prostate cancer continuum need education that strengthens multidisciplinary, patient-centered care. This includes integrating APPs, caregiver perspectives, and holistic wellness approaches; interpreting and applying novel diagnostics such as PSMA imaging, molecular markers, AI tools, PET, and MRI; and understanding how genomic findings inform personalized treatment decisions. Providers also need updated guidance on selecting and sequencing treatments for localized disease, hormone-sensitive prostate cancer, and castration-resistant prostate cancer, including the use of systemic and radioligand therapies.

Additionally, clinicians require clearer insight into the health policy landscape—reimbursement models, advocacy strategies, and the broader political forces that shape patient access to care and innovation. They also need support in managing the short- and long-term side effects of ADT, using evidence-based, multidisciplinary strategies that preserve quality of life and promote survivorship.

Learning Objectives

1. Apply new evidence and guidelines to personalize prostate cancer treatment across localized, hormone-sensitive, and castration-resistant disease.
2. Evaluate the role of imaging modalities (PSMA PET, MRI) and emerging biomarkers in diagnosis and monitoring.
3. Interpret genomic and AI-driven data to inform precision medicine decisions.
4. Incorporate strategies to manage ADT side effects and promote survivorship health.
5. Demonstrate collaborative and advocacy-based approaches to improve access, reimbursement, and quality of care in prostate oncology.
6. Integrate APP-directed and multidisciplinary models to enhance care efficiency and outcomes.
7. Engage patients and caregivers in shared decision-making to support holistic, compassionate care.

List of Speakers

Program Chair

E. David Crawford, MD

Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus
Denver, CO

Co-Chairs

Scott Sellinger, MD, FACS

Partner, Advanced Urology Institute
Tallahassee, FL

David Morris, MD

President and the Co-Director for the Advanced Therapeutics Center at Urology Associates
Nashville, TN

Invited Faculty

David Albala, MD

Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals
Syracuse, NY

Marijo Bilusic, MD, PhD

Genitourinary Medical Oncology Team Lead, Sylvester Comprehensive Cancer Center
Professor of Clinical Medicine, University of Miami Health System
Former Program Director, NIH Hematology-Oncology Fellowship
Miami, FL

Reena Cherry, PA-C

Physician Assistant, UC San Diego Health
San Diego, CA

Adam Cole, MD, MS

Founder & Chief Executive Officer, TruCore Pathology
Board-Certified Pathologist, Genitourinary & Molecular Pathology
Little Rock, AR

Sean Collins, MD

Chair of the Programmatic Panel for the Department of Defense (DOD) Prostate Cancer Research Program
Tampa, Florida

Matthew R. Cooperberg, MD, MPH

Chief of Urology, San Francisco VA Medical Center
Urology Co-Leader, Prostate Program, UCSF Helen Diller Family Comprehensive Cancer Center
Professor of Urology & Epidemiology/Biostatistics, University of California, San Francisco
San Francisco, CA

Scott Eggener, MD

Professor and Chair, Department of Urology, UCLA Associate Editor, The Journal of Urology (Prostate Cancer)
Los Angeles, CA

Sherief Gamie, MD, PhD

Chief & Medical Director, Nuclear/Molecular Imaging and Theranostics Program, UC San Diego
Professor of Clinical Radiology, University of California San Diego
San Diego, CA

Evan R. Goldfischer, MD, MBA, MPH, FACS, CPE

LUGPA Past President; Co-Founding CEO, Premier Medical Group of the Hudson Valley
Pleasant Valley, New York

Jason H. Hafron, MD

Chief Medical Officer & Director of Clinical Research, Michigan Institute of Urology
Professor of Urology, Oakland University
William Beaumont School of Medicine
Royal Oak, MI

Ronald P. Kaufman Jr., MD

Professor of Surgery (Urology), Albany Medical College
Past President, New York State Urological Society & AUA Northeastern Section
Albany, NY

Michael Liss, MD, PhD, MAS, FACS

Urologic oncologist, UT Health MD
Anderson Center
San Antonio, TX

Benjamin H. Lowentritt, MD, FACS

Director, Minimally Invasive Surgery and Robotics
Director, Prostate Cancer Care Program, Chesapeake Urology
Past President, AUA Mid-Atlantic Region
Board of Directors, LUGPA
Baltimore, MD

Bryan Mehlhaff, MD

Medical Director of Research, Oregon Urology Institute
President, Oregon Urology Institute
Former Board Member, LUGPA | Oregon Urology Society
Eugene, OR

Travis Mendel, MD

Medical Director, Rio Grande Cancer Specialists
Board-Certified Radiation Oncologist
El Paso, TX

Todd Morgan, MD

Jack Lapides, M.D. Research Professor, Chief of Urologic Oncology and Co-Director of the Weiser Center for Prostate Cancer at the University of Michigan
Ann Arbor, MI

Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PM

Adjunct Professor of Surgery (Urology), Perelman School of Medicine, University of Pennsylvania
Internationally Recognized Expert in Pelvic Floor Disorders & Bladder Dysfunction
Philadelphia, PA

William Parker, MD

Urologist at The University of Kansas Health System and Associate Professor at the University of Kansas Medical Center
Kansas City, KS

Daniel P. Petrylak, MD

Professor of Medicine Medical Oncology and Urology Yale School of Medicine
New Haven, CT

Accreditation and Designation Statements and Disclosure Report

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUGPA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of 9.25 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The live approval period is: January 10-13, 2026

The enduring approval period is: February 10, 2026 – February 10, 2029



Accreditation and Designation Statements and Disclosure Report

Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

FULL LEGAL NAME	COMMERCIAL INTEREST	ROLE	Level of participation in the activity
David Albala, MD	Applied Medical MDx Health	Stock/Stock Options Researcher/Investigator	Speaker
Marijo Bilusic	Bicycle Therapeutics Pfizer Clasp Therapeutics Hookipa Pharma Eli Lilly Marengo Therapeutics Surface Oncology Merck Sharp & Dohme	Research Funding	Speaker
Renee Cherry, PA-C	Tolmar	Consultant	Speaker
Julio Davalos, MD	Boston Scientific	Consultant	Speaker
Matthew Cooperberg	Exosome Astellas Amgen Janssen Veracyte GSK Pfizer LynxDx	Consultant	Speaker
Sean Collins	Boston Scientific Bioprotect Astellas/Pfizer MDxHealth Clarity Pharmaceuticals	Consultant	Speaker
Scott Eggener	Janssen/Johnson & Johnson A3P biomedical Janssen	Advisor Consultant	Speaker
Jason Hafron	Candel Therapeutics Novartis Urogen Bayer Myriad Dendreon Janssen Biotech Astellas Immunis AI Scientific AZ Merck Photocure Lilly ArteraAI Sumitomo	Researcher/Investigator Consultant	Speaker

Accreditation and Designation Statements and Disclosure Report

Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

FULL LEGAL NAME	COMMERCIAL INTEREST	ROLE	Level of participation in the activity
Ron Kaufman	Lipella mIR Scientific Progenics Clarity Ferring SUO-CTCECOG-ACRIN, Stebabiotech Becton, Dickinson and Company Pacific Edge Diagnostics enGene Janssen	Research Funding	Speaker
Michael Liss	Oncobiomix	Ownership Interest	Speaker
Benjamin Lowentritt	Pfizer, Sumitomo Pharma Astellas Merck AstraZeneca Bayer	Advisor	Speaker
Travis Mendel	GE Novartis BostonSci Novartis BioProtect	Advisor Researcher/Investigator Consultant	Speaker
Todd Morgan	Pfizer Johnson & Johnson Merck Foundation Medicine	Consultant	Speaker
David Morris	Pfizer Merck AZ Bayer Dendreon Decipher Telix Johnson & Johnson Caris Sumitomo Veritas Astellas	Consultant	Speaker. Planner/Reviewer

Accreditation and Designation Statements and Disclosure Report

Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

FULL LEGAL NAME	COMMERCIAL INTEREST	ROLE	Level of participation in the activity
Diane Newman	NIH Hollister Sumitomo COSM Innocare Convatec Urology Health Advisor Grand Rounds in Urology	Researcher/Investigator Advisor Editor	Speaker
Scott Sellinger	Avyxa Astellas Sumitomo Bayer Foundation Medicine Tempus MDX Health Accord Biopharma AZ Johnson & Johnson Pfizer	Consultant	Speaker, Planner/Reviewer

These financial relationship(s) with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the LUGPA.

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Agenda

Saturday, January 10, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
5:00 p.m. – 7:00 p.m.	Meeting Registration / Information	Deer Creek Foyer
6:00 p.m. – 7:00 p.m.	Welcome and Networking Reception in the Exhibit Hall <i>(no scheduled event)</i>	Deer Creek Ballroom

Sunday, January 11, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
6:15 a.m. – 3:30 p.m.	Meeting Registration / Information	Deer Creek Foyer
6:15 a.m. – 6:45 p.m.	Coffee in Exhibit Hall	
6:45 a.m. – 7:00 a.m.	Welcome and Introductions Program Chair: E. David Crawford, MD	Deer Creek Ballroom
7:00 a.m. – 8:00 a.m.	Session 1: Integrated Cancer Care Moderator: Michael Liss, MD, PhD 7:00 a.m. – 7:10 a.m. Diet/Microbiome – Implications for Prevention Speaker: Michael Liss, MD PhD 7:10 a.m. – 7:20 a.m. APP Directed Clinics Speaker: Diane Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD 7:20 a.m. – 7:30 a.m. Testosterone Replacement Therapy and Prostate Cancer Speaker: William Parker, MD 7:30 a.m. – 7:40 a.m. Caregiver Perspective Speaker: Renna Cherry, PA-C 7:40 a.m. – 8:00 a.m. Provider and Patient Journey Speakers: Bryan Mehlhaff, MD and his Patient Larry Ferguson	Deer Creek Ballroom

Sunday, January 11, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
8:00 a.m. – 8:45 a.m.	Industry Symposium Breakfast Bayer Sponsored Product Theater David Crawford, MD Sponsored by Bayer	Jordanelle DEF
8:45 a.m. – 9:15 a.m.	Exhibit Hall	
9:15 a.m. – 10:00 a.m.	Session 2: Advanced Diagnostics Moderator: Matthew Cooperberg, MD 9:15 a.m. – 9:25 a.m. PSMA-guided Approaches Speaker: Sherief Gamie, MD, PhD 9:25 a.m. – 9:35 a.m. Pre-biopsy Markers Speaker: E. David Crawford, MD 9:35 a.m. – 9:45 a.m. PTEN Testing and AI Speaker: Adam Cole, MD 9:45 a.m. – 9:55 a.m. AI and Post-Biopsy Speaker: Matthew Cooperberg, MD 9:55 a.m. – 10:30 a.m. Point Counterpoint: Transperineal is superior to Transrectal Panel Discussion / Challenging Cases Moderator: David Albala, MD Panelists: William Parker, MD, and Ron Kaufman, MD Selected Recorded Abstracts	Deer Creek Ballroom
10:30 a.m. – 3:30 p.m.	Free Time	
3:30 p.m. – 4:15 p.m.	Mid-Day Industry Symposium Moving Forward With the First and Only PSMA-Targeted-Therapy After One ARPI Bryan A. Mehlhaff, MD Sponsored by Novartis Pharmaceuticals Corporation	Jordanelle DEF

Sunday, January 11, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
4:15 p.m. – 5:15 p.m.	<p>Session 3: Imaging Moderator: Sherief Gamie, MD, PhD</p> <p>4:15 p.m. – 4:25 p.m. New PET tracers – What's to Come Moderator: Sherief Gamie, MD, PhD</p> <p>4:25 p.m. – 4:35 p.m. How Non-Radiologists Can Interpret and Read PET Speaker: Sherief Gamie, MD, PhD</p> <p>4:35 p.m. – 4:45 p.m. PET and Radiation Speaker: Sean Collins, MD</p> <p>4:45 p.m. – 4:55 p.m. MRI Imaging Speaker: Michael Liss, MD, PhD</p> <p>4:55 p.m. – 5:15 p.m. Panel Discussion / Q&A Moderator: Sherief Gamie, MD, PhD Panelists: Travis Mendel, MD, Sean Collins, MD, Michael Liss, MD, PhD</p> <p>Selected Recorded Abstracts</p>	Deer Creek Ballroom
5:15 p.m. – 6:00 p.m.	Exhibit Hall Break	
6:00 p.m. – 6:45 p.m.	<p>Session 4: Health Policy and Political Advocacy Moderator: Scott Sellinger, MD</p> <p>6:00 p.m. – 6:45 p.m. Panel Discussion / Q&A Panelists: David Albala, MD, Jason Hafron, MD, Ben Lowentritt, MD, Evan R. Goldfischer, MD</p> <p>6:45 p.m. – 6:50 p.m. Conclusion and Highlights of the Next Day</p> <p>7:00 p.m. – 8:30 p.m. Industry Night at the Hidden Ace Sponsored by Avyxa</p>	Deer Creek Ballroom

Monday, January 12, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
6:30 a.m. – 3:30 p.m.	Meeting Registration / Information	Deer Creek Foyer
6:30 a.m. – 7:00 a.m.	Coffee in Exhibit Hall	
7:00 a.m. – 8:00 a.m.	Session 5: Genetics/Genomics Moderator: Scott Eggener, MD 7:00 a.m. – 7:10 a.m. Myths in Prostate Cancer Screening and the Role of Biomarkers Moderator: Scott Eggener, MD 7:10 a.m. – 7:20 a.m. Pathology and Artificial Intelligence Speaker: Adam Cole, MD 7:20 a.m. – 7:30 a.m. Genomics in Advanced Prostate Cancer Speaker: Todd Morgan, MD 7:30 – 8:00 a.m. Panel Discussion / Q&A / Case Presentations Moderator: Scott Eggener, MD Panelists: Jason Hafron, MD, Ben Lowentritt, MD, Todd Morgan, MD, Adam Cole, MD Selected Recorded Abstracts	Deer Creek Ballroom
8:00 a.m. – 8:45 a.m.	Breakfast Industry Symposium: Head-to-head overall survival data in mCSPC: A review of real-world evidence Speaker: David Morris, MD Sponsored by Johnson & Johnson	Jordanelle DEF
8:45 a.m. – 9:15 a.m.	Exhibit Hall	

Monday, January 12, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
9:15 a.m. – 10:15 a.m.	Session 6: Localized Prostate Cancer Moderator: William Parker, MD 9:15 a.m. – 9:25 a.m. Advances in Radiation Speaker: Sean Collins, MD 9:25 a.m. – 9:35 a.m. Management of Low-risk Disease Speaker: Scott Eggener, MD 9:35 a.m. – 9:45 a.m. Modifications of Prostatectomy Speaker: William Parker, MD 9:45 a.m. – 9:55 a.m. Managing Incontinence Speaker: Diane Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD 9:55 a.m. – 10:15 a.m. Panel Discussion / Q&A Moderator: Ben Lowentritt, MD Panelists: Sean Collins, MD, Scott Eggener, MD, William Parker, MD, Diane Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD Selected Recorded Abstracts	Deer Creek Ballroom
10:30 a.m. – 3:30 p.m.	Free Time	
10:30 a.m. – 3:30 p.m.	Mid-Day Industry Symposium: Treatment Intensification for Patients with Metastatic Castration-Sensitive Prostate Cancer and Nonmetastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence at High Risk for Metastasis Speaker: Aaron Berger, MD Sponsored by Astellas Oncology & Pfizer Oncology	Jordanella DEF

Monday, January 12, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
4:30 p.m. – 5:30 p.m.	<p>Session 7: Hormone-Sensitive Prostate Cancer Moderator: Scott Sellinger, MD</p> <p>4:30 p.m. – 4:40 p.m. From Monotherapy to Quadruple Therapy Speaker: E. David Crawford, MD</p> <p>4:40 p.m. – 4:50 p.m. ADT updates Speaker: Marijo Bilusic, MD</p> <p>4:50 p.m. – 5:00 p.m. What to Expect in 2026 Speaker: Scott Sellinger, MD</p> <p>5:00 p.m. – 5:10 p.m. Urology Theranostics Center Speaker: Travis Mendel, MD</p> <p>5:10 p.m. – 5:20 p.m. Metastasis Directed Therapy Speaker: Bryan Mehlhaff, MD</p> <p>5:20 p.m. – 5:40 p.m. Panel Discussion / Q&A / Case Discussion Moderator: Bryan Mehlhaff, MD Panelists: E. David Crawford, MD, Marijo Bilusic, MD, Travis Mendel, MD</p> <p>Session 7 Recorded Abstracts</p>	Deer Creek Ballroom
5:40 p.m. – 7:00 p.m.	Welcome Reception in Exhibit Hall	

Tuesday, January 13, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
6:30 a.m. – 10:30 a.m.	Meeting Registration & Information	Deer Creek Foyer
7:00 a.m. – 8:00 a.m.	Session 8: CRPC and Next-Line Therapy Moderator: Daniel Petrylak, MD 7:00 a.m. – 7:10 a.m. Radioligand Therapy Speaker: Sherief Gamie, MD, PhD 7:10 a.m. – 7:20 a.m. PARP Inhibitors Speaker: Daniel Petrylak, MD 7:20 a.m. – 7:30 a.m. What's Coming Next in Urology Clinics Speaker: Daniel Petrylak, MD 7:30 a.m. – 7:40 a.m. Somatic Testing on Progression Speaker: Todd Morgan, MD 7:40 a.m. – 8:10 a.m. Panel Discussion / Q&A Moderator: Daniel Petrylak, MD Panelists: Sherief Gamie, MD, PhD, Todd Morgan, MD Session 8 Selected Recorded Abstracts	Deer Creek Ballroom
8:10 a.m. – 8:45 a.m.	Breakfast Industry Symposium: Treatment of mCRPC: Results From Key Clinical Trials Speaker: Scott Sellinger, MD Sponsored by AstraZeneca	Jordanelle DEF

Tuesday, January 13, 2026

* Please note that speakers and agenda topics are subject to change

TIME	SESSION TITLE	LOCATION
8:45 a.m. – 9:45 a.m.	Session 9: ADT Side Effects Moderator: Jason Hafron, MD 8:45 a.m. – 8:55 a.m. APP Management Speaker: Diane Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD and Renna Cherry, PA-C 8:55 a.m. – 9:05 a.m. Prostate Cancer 360 Update Speaker: Jason Hafron, MD 9:05 a.m. – 9:15 a.m. Cardio-Oncology and Androgen Deprivation Therapy Speaker: David Morris, MD 9:15 a.m. – 9:45 a.m. Panel Discussion / Q&A Moderator: Jason Hafron, MD Speakers: Diane Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD, Renna Cherry, PA-C, David Morris, MD 9:45 a.m. – 10:30 a.m. Session 9 Selected Abstracts	Deer Creek Ballroom
10:30 a.m.	Conclusion / Closing Remarks	

How to Obtain Your CME Certificate

CME credit for GPCC 2026 will be available to claim beginning **January 19, 2026**.

1. **Open your web browser** and go to: **peerptlogin.com**
2. **Log in** using the following credentials:
 - **Email:** Your registered email address
 - **Password:** Your First Name (case-sensitive)
3. **Navigate to the “Videos/Surveys/Tests” tab.**
4. **Click on:** “Click here to take survey” (this will open the survey).
5. **Complete the survey** and select “Save.”
6. **Go to the “Print CME Certificates” tab.**
7. Next to the conference description, select **“Assign Credit Hours.”**
8. A window will open displaying the maximum credit hours available for the conference.
 - If you attended the entire conference, select the maximum hours from the dropdown.
 - If you attended only part of the conference, select the actual number of hours you attended.
9. Select **“Save Credit Hours.”**
10. Click **“View/Print.”**
11. Depending on your device:
 - The CME Certificate PDF will either download automatically, or
 - A window will open prompting you to download the certificate. Select **“Save File.”**

Sunday, January 11, 2026

8:00 a.m. — 8:45 a.m. | Jordanelle DEF



Bayer Sponsored Product Theater

David Crawford, MD

3:30 p.m. — 4:15 p.m. | Jordanelle DEF



Moving Forward With the First and Only PSMA-Targeted-Therapy After One ARPI

Bryan A. Mehlhaff, MD

Monday, January 12, 2026

8:00 a.m. — 8:45 a.m. | Jordanelle DEF



Head-to-head overall survival data in mCSPC: A review of real-world evidence

David Morris, MD

3:30 p.m. — 4:30 p.m. | Jordanelle DEF



**Treatment Intensification with XTANDI (Enzalutamide) for
Patients with Metastatic Castration-Sensitive Prostate Cancer &
Nonmetastatic Castration-Sensitive Prostate Cancer with
Biochemical Recurrence at High Risk for Metastasis**

Aaron Berger, MD

Tuesday, January 13, 2026


8:10 a.m. — 8:45 a.m. | Jordanelle DEF



Treatment of mCRPC: Results From Key Clinical Trials

Scott B. Sellinger, MD

Floor Plan



INDUSTRY PARTNER

TABLE

AbbVie	20
Angiogenesis Analytics	36
Artera	34
Astellas Oncology & Pfizer Oncology	38
AstraZeneca	21
Avyxa	5
Bayer	31
Biobot Surgical U.S. Inc.	35
Blue Earth Diagnostics	32
Caris Life Sciences	17
Clarity Pharmaceuticals	28
Cleveland Diagnostics	30
Coloplast	33
Curium	11
Doc Lab Inc.	6
Francis Medical	22
Johnson & Johnson	3

INDUSTRY PARTNER

TABLE

Lantheus	39
Lumea	18
mdxhealth	40
MiRNA Scientific, Inc.	15
Myriad Oncology	37
Novartis Pharmaceuticals Corporation	4
PathRight Medical	29
Pfizer Oncology	26
Sumitomo Pharma America	7
Teleflex	24
Telix Pharmaceuticals	2
Theragenics	25
Tolmar, Inc.	16
UroNova Pharmaceuticals, Inc.	1
Veracyte	19
Vision RT	27
Xaga Surgical	23

Thank you to our LUGPA 2026 Global Prostate Cancer Congress Exhibitors

Gold Partners

Astellas Oncology & Pfizer Oncology
AstraZeneca
Bayer

Johnson & Johnson
Novartis Pharmaceuticals
Corporation

Silver Partners

Curium
Lantheus

Telix Pharmaceuticals
Tolmar, Inc.

Bronze Partners

Avyxa

Pfizer Oncology

Exhibitors

AbbVie
Angiogenesis Analytics
Artera
Biobot Surgical U.S. Inc.
Blue Earth Diagnostics
Caris Life Sciences
Clarity Pharmaceuticals
Cleveland Diagnostics

Coloplast
Doc Lab Inc.
Francis Medical
Lumea
mdxhealth
MiRNA Scientific, Inc.
Myriad Oncology
PathRight Medical

Sumitomo Pharma America
Teleflex
Theragenics
UroNova Pharmaceuticals, Inc.
Veracyte
Vision RT
Xaga Surgical



LUGPA
Integrated Practices
Comprehensive Care

Faculty Biographies



David M. Albala, MD

Dr. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He was on the team that performed the first laparoscopic nephrectomy in the world at Washington University. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. Ten years later, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 275 publications in peer-reviewed journals and has authored three textbooks in endourology and nine in general urology. He is the Editor-in-Chief of the Journal of Robotic Surgery. He serves on the editorial board for Medical Reviews in Urology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. He is a Visiting Professor in the Department of Urology at SUNY Downstate Health Sciences University. In addition, he was ranked among the top 2% of urologists in the world by a Stanford University study done in May 2021.

At the present time he is Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 21 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment

of benign prostatic hypertrophy (BPH), biomarkers in prostate cancer, and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 19 fellows in endourology and advanced robotic surgery.

In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.



Marijo Bilusic, MD, PhD

Dr. Bilusic is a board-certified medical oncologist who treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, immune modulators or immune checkpoint inhibitors, not only as monotherapies but in combination with other therapies as part of an immunoncology programmatic effort.

Dr. Bilusic received his M.D. degree from the University of Zagreb School of Medicine in Croatia and completed his Ph.D. training at the University of Split School of Medicine in Croatia. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. He successfully completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI), in Bethesda, MD.

Dr. Bilusic served as an assistant professor Genitourinary medical oncology) at the Fox Chase Cancer Center/Temple Health from 2012 – 2016 and then joined the NCI Genitourinary Malignancy Branch in 2016 as an Associate Research Physician (equivalent to Associate Professor). During his time at the NCI, he also served as Associate Program Director, NIH Hematology Oncology Fellowship Program from July 2016 – July 2018, and then as Program Director from July 2018 – July 2021. In 2017 Dr. Bilusic received the National Institutes of Health (NIH) Director's Award as a member of NIH Hematology Oncology Fellowship Team for extraordinary resourcefulness and initiative. His passion for teaching and mentoring has earned multiple awards at NIH and NCI.

In July 2021, Dr. Bilusic joined Sylvester Comprehensive Cancer Center / University of Miami Health System as GU Medical Oncology Team Lead and Professor of Clinical Medicine. He is board-certified in medical oncology, hematology, and internal medicine.



Reena Cherry, PA-C

Reena Cherry is a highly accomplished board-certified surgical and medical oncology Physician Assistant with a distinguished career spanning 24 years in the oncology space. Throughout this time, Reena has served patients as an expert clinician at two of the nation's most prestigious healthcare institutions: MD Anderson Cancer Center and UC San Diego Health. Reena brings a wealth of experience to the field of oncology, specializing in prostate cancer, bladder cancer, kidney cancer, and testicular cancer. With a deep commitment to compassionate patient care, Reena also dedicates her time to supporting the needs of formal and informal caregivers who are, in many ways, the backbone of our healthcare system. Reena received her bachelor

of science degree in Psychology from Spelman College in Atlanta, Georgia and her master of science degree in Physician Assistant studies at Baylor College of Medicine in Houston, Texas. Reena is a member of the American Association of Physician Assistants (AAPA), the Association for Physician Assistants in Oncology (APAO), the California Association of Physician Assistants (CAPA), and the Schwartz Center for Compassionate Healthcare. Additionally, Reena holds board appointments on the Prostate Conditions Education Council, the Jack A. Vickers Scientific Advisory Board, and the Kidney Cancer Association Clinical Advisory Board.



Adam Cole, MD, MS

Today, Dr. Cole reads more than 60,000 prostate samples every year for urology groups in nine states—including Urology Partners of North Texas. By focusing exclusively on prostate pathology, he has been able to define a new space where biomarkers are used in conjunction with traditional Gleason grading—adding clarity to the inherent subjectivity associated with traditional prostate cancer grading.

As active surveillance becomes more prevalent and guidelines from the National Comprehensive Cancer Network (NCCN) continue to evolve, Dr. Cole is an active participant in determining when biomarkers are appropriate (based on tissue examined under the microscope). Since reflex ordering is rightfully frowned upon, Dr. Cole also considers a patient's age, PSA, tumor volume, grade, tumor phenotype (within Gleason grade 4 disease) and current NCCN guidelines when recommending or ordering a biomarker.

Dr. Cole earned a bachelor's degree in microbiology at the University of Arkansas in Fayetteville, where he graduated with honors. He completed his master's degree in health science at Duke University in Durham, North Carolina. Afterward,

he earned his medical degree at Louisiana State University Health Sciences Center in Shreveport, and completed his residency in pathology at the University of Arkansas for Medical Sciences. He is a board-certified pathologist with a focus in genitourinary and molecular pathology.

Dr. Cole lives in Little Rock, Arkansas, and serves in the United States Air Force Reserves as a lieutenant colonel and squadron commander of the 44th AMDF/301FW at Eglin Air Force Base. In his free time, he enjoys fly fishing and getting his money's worth on the golf course.



Sean Collins, MD

Dr. Collins is a highly accomplished radiation oncologist, most recently serving as the director of the CyberKnife Prostate Program at MedStar Georgetown University Hospital in Washington, D.C. With board certification from the American Board of Radiology in Radiation Oncology, Dr. Collins has dedicated over two decades to advancing the treatment of prostate cancer. Specifically, he has treated over 2500 men with prostate cancer utilizing the CyberKnife. He has been at the forefront of innovative radiation therapies, earning him recognition as a Washingtonian Top Doctor since 2015.

In addition to his clinical expertise, Dr. Collins is a prolific researcher and educator, contributing to national and international efforts to improve cancer treatment outcomes. He has published over 300 peer reviewed articles and abstracts many of with evaluated patient reported outcomes (PRO) following prostate cancer treatment. He has obtained grant funding from the National Cancer Institute focusing on determinants of racial disparity in prostate cancer. Has served as an active member of the Alliance in Oncology Radiation Oncology and GU Committees since 2010. He currently serves on the steering committee for two trials assessing the potential

benefits of rectal spacers with prostate radiotherapy. Most recently he was selected as incoming Chair of the Programmatic Panel for the Department of Defense (DOD) Prostate Cancer Research Program. Recognized for his leadership in prostate cancer care, Dr. Collins continues to push the boundaries of cancer treatment, while mentoring the next generation of radiation oncologists.



Matthew Cooperberg, MD

Dr. Cooperberg graduated from Dartmouth College, where he finished *summa cum laude* with a major in English. He earned his MD and MPH degrees at Yale University, and completed residency in Urology and fellowship in Urologic Oncology at UCSF. At the end of his training, Dr. Cooperberg joined the faculty at UCSF in 2009. He is Chief of Urology at the San Francisco VA Medical Center, and he maintains busy clinical practices both there and at the UCSF Helen Diller Family Comprehensive Cancer Center, where he is the Urology co-Leader of the Prostate Program. He also holds a secondary appointment in the Department of Epidemiology & Biostatistics.

He is actively engaged in research approaching the challenges of prostate cancer from many interrelated perspectives, from molecular analyses to health system-wide research. He has written or contributed to over 550 research articles addressing health services, outcomes, risk stratification, comparative effectiveness, biomarkers, and other domains. Early in 2013 Dr. Cooperberg co-authored a proposal for a national urology registry which served as the basis for the AUA Quality (AQUA) Registry and served as Senior Physician Advisor over the first decade of the project. In 2015 he won the AUA Gold Cystoscope, awarded to one urologist annually based on impact to the field in the first ten years after training. He has served as Principal Investigator

on major grants from National Cancer Institute, Department of Defense, and Centers for Disease Control.

He lives in San Francisco with his wife, Jacqueline Dolev (a dermatologist and fellow Yale Medical School alum), where they work primarily to keep up with their children, Jake (16) and Sarah (12).



E. David Crawford, MD

Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher. He has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, one of the Top 20 Urologists in the county by Men's Health Magazine, and recently selected as the Healthcare Provider of the Year in the Denver Metro Area by *The Denver Business Journal*. In addition, he is the recipient of more than 95 research grants in the diagnosis and treatment of prostate cancer, metastatic prostate cancer, hormone refractory prostate cancer, benign prostatic hyperplasia (BPH), advanced bladder cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 600 published articles, contributed to nearly 100 educational books and provided thousands of educational talks for patients and physicians.

In an effort to raise awareness and education about prostate health, Dr. Crawford founded and is the current Chairman of the Prostate Conditions Education Council, a non-profit organization which is responsible for reaching an average of 400 million people each year with education and awareness information.

On prostate cancer and men's health issues, his involvement in the national prostate cancer arena has been widely recognized and he is often

requested to act as an educator, speaker, participate in advisory boards, review research or serve as a legal expert.

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science.



Scott Eggener, MD

Dr. Eggener is Professor and Chair of the Department of Urology at UCLA. His research focuses on prostate and testicular cancer, with particular focus on reducing the overdiagnosis and overtreatment of prostate cancer and an emphasis on clinical trials. His work has led to more than 350 publications in leading journals including *JAMA*, *JNCI*, and *NEJM*, and has been featured in national media outlets such as *The New York Times* and *The Wall Street Journal*.

He serves as Associate Editor at the *Journal of Urology* (Prostate cancer) and has served on multiple cancer guideline panels for the American Society of Clinical Oncology, American Urological Association, and National Comprehensive Cancer Network.



Sherief Gamie, MD, PhD. Chief – Medical Director of Nuclear / Molecular Imaging and Theranostics Program (UCSD)

Dr. Gamie is a board certified nuclear medicine physician. Nuclear Medicine is a specialized area of medicine that utilizes small amounts of radiopharmaceuticals (radioactive materials) to diagnose and treat diseases. Dr. Gamie is also a diplomat of the Certification Board of Nuclear Cardiology and

subspecializes in nuclear and PET/CT cardiac imaging. Dr. Gamie's professional subspecialty expertise and passion is in Molecular Imaging and theranostics applying precision targeted radiopharmaceuticals in the diagnosis and treatment of numerous malignancies for which he trained and practiced at Stanford University.

He completed his residency in nuclear medicine at USC in Los Angeles and earned his medical degree from one of the world's oldest Medical Schools in the world, Faculty of Medicine, Alexandria University, Egypt (established in 1938). He also performed two consecutive Fellowships, one in PET/CT at USC and second in Radiation Oncology / Brachytherapy at UCI. Dr. Gamie earned his PhD as part of a joint program between University of California Irvine and Alexandria University, examining the physical and therapeutic properties of low and high dose rate brachytherapy volumetric dosimetry in the treatment of pelvic malignancies.



Evan P. Goldfischer, MD, MBA, CPI, MPH
Dr. Goldfischer received his BA from Tufts University and his MD from Cornell University Medical College. He completed his internship in general surgery and his residency in urology at the University of Chicago. He completed a fellowship in endourology under the direction of Arthur Smith at Long Island Jewish Medical Center. Dr. Goldfischer received his MBA from the University of Massachusetts and is a Certified Physician Executive. He served as the co-founding CEO of Premier Medical Group of the Hudson Valley, as well as founding Director of Research.

Dr. Goldfischer has written over 100 peer-reviewed abstracts and publications and has lectured on six continents. In addition, he was elected to the LUGPA Board of Directors in 2014 currently serving as Past-President. He is the Editor-in-Chief of Practice Management for

Urology Groups: LUGPA's Guidebook Third Edition published in 2024 and is the author of *Even Urologists Get Kidney Stones – A Guide to Prevention and Treatment*, published in 2018.



Jason M. Hafron, MD
Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology (MIU). Dr. Hafron is a Professor of Urology at the William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan. He is experienced in all areas of adult urology, specializing in the minimally invasive treatment of cancers involving the prostate, kidney and bladder utilizing robotic surgery.

Dr. Hafron received his Bachelor of Science degree from the University of Michigan and his Doctor of Medicine degree from Loyola University Chicago-Stritch School of Medicine. Dr. Hafron completed his General Surgery and Urology Residency at Albert Einstein College of Medicine, Montefiore Medical Center in New York City. He continued his training as a Fellow in Advanced Laparoscopic and Robotic Surgery at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, Ohio. Dr. Hafron has published numerous peer reviewed journal articles on topics related to his expertise and presented his work at many national and international scientific meetings. He is the recipient of many clinical research awards. He is on the Editorial Board of the journal *International Urology and Nephrology*, *Urologists in Cancer Care* and *Advances in Urology*. He previously served on the Board of Directors of United Physicians Organization. Dr. Hafron is board certified in the specialty of Urology by the American Board of Urology.



Ronald P. Kaufman Jr., MD

Dr. Kaufman is a Professor of Surgery in the Department of Urology at Albany Medical College in Albany, New York. He received his undergraduate degree from Trinity College and his medical degree at George Washington University. He completed his internship and residency in surgery at Case Western Reserve-Integrated Hospitals of Cleveland, a research fellowship at The Harvard Medical School-Brigham and Women's Hospital and his Urology residency at Duke University. He then joined the faculty at Albany Medical College. Early in his career he was the Interim Chair of the Division of Urology. Recently he briefly was a medical director with Neotract / Teleflex. He currently maintains a practice primarily in urologic oncology. He is the author of 200 peer-reviewed articles.

Dr. Kaufman was a member of the inaugural AUA Leadership Program in 2004. He has served on numerous AUA committees, including Chair of the AUA Coding and Reimbursement Committee and service as a consultant to the AMA Current Procedural Terminology (CPT) Editorial Panel. He is a past president of the New York State Urological Society and the Northeastern Section of the AUA.



Michael Liss, MD, PhD, MAS, MBA

Dr. Liss is a surgeon scientist at the University of California San Diego, specializing in prostate cancer. His research interests include the application of the microbiome in clinical care, genetics, and MRI imaging. He has received funding from the DOD and NCI and was previously awarded the prestigious NCI Team Leadership Award. He has held leadership roles such as Medical Director of the Clinical Trials Office at

Mays Cancer Center and is currently the Director of Microbiome Clinical Trials at the Center for Microbiome Innovation at UCSD. He holds a PhD in translational science from the University of Texas, Austin College of Pharmacy, with an emphasis on drug development, and an MBA from UT San Antonio for application in scientific commercialization.



Ben Lowentritt, MD

Dr. Benjamin Lowentritt serves as the Medical Director of the Comprehensive Prostate Cancer Care Program at Chesapeake Urology Associates, a member of United Urology's group practices. He also serves as Senior Vice-President of Practice Development and Director of Prostate Cancer Services for United Urology Group. Dr. Lowentritt is a member of United Urology's Executive Leadership Team.

In his role, Dr. Lowentritt has worked with member practices to build and optimize services for prostate cancer patients. This includes supporting physicians, staff, and operational teams treatment options are expanded. The goal is for each member group to have a comprehensive, state-of-the-art program that helps patients through a complex diagnosis. He is also directing Disease-State-Management programs for other conditions commonly treated by urologists.

Dr. Lowentritt received his Doctor of Medicine degree from Baylor College of Medicine, completed his medical residency at the University of Maryland School of Medicine and a fellowship in Robotic, Laparoscopic and Endoscopic Urology at Tulane University. His practice focuses on evaluation and management of prostate cancer through all stages of the disease.

Dr. Lowentritt is a Past-President of MedChi, the Maryland State Medical Society and is a Board member of the Large Urology Group Practice Association (LUGPA), currently

serving as Secretary. He is a Past-President of the Mid-Atlantic Section of the American Urological Association and of the Baltimore City Medical Society. He is the Medical Director for Urology for Cencora. He has been recognized as a Top Doctor in multiple publications.



Bryan Mehlhaff, MD

A native of Oregon, Dr. Mehlhaff attended Beloit College in Wisconsin followed by medical school at Oregon Health Sciences University. After completing general surgery and urology residency at Albany Medical Center, he joined the Department of Urology as an Assistant Professor. For the past 27 years he has practiced in Eugene, Oregon. At Oregon Urology Institute as Medical Director of Research, he oversees numerous clinical trials in advanced prostate cancer and benign prostate conditions. Dr. Mehlhaff is also president of OUI. He is a past Board member of LUGPA and the Oregon Urology Society.



Jameson Travis Mendel, MD

Dr. Mendel is a Board-Certified Radiation Oncologist with extensive training and expertise. He completed his Residency in Radiation Oncology at the University of Texas Southwestern Medical Center in Dallas, following his internship at Tucson Hospital Medical Education Program in Tucson, Arizona. Dr. Mendel earned his M.D. from the Paul L. Foster School of Medicine at Texas Tech University Health Science Center in El Paso, Texas, and holds a B.S. in Biochemistry from the University of Puget Sound in Tacoma, Washington.

Dr. Mendel has several advanced therapeutic certifications, as well as several Center of Excellence

recognitions. His specialty focus covers a wide range of advanced radiation therapies, including Three Dimensional Radiotherapy (3DRT), Intensity-Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), Stereotactic Body Radiation Therapy (SBRT), and Stereotactic Radiosurgery (SRS).

Dr. Mendel serves as the Medical Director of Rio Grande Cancer Specialists.



Todd M. Morgan, M.D.

Dr. Morgan is a urological surgeon specializing in the treatment of genitourinary malignancies. Dr. Morgan is originally from Seattle, WA, and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. Dr. Morgan is a translational surgeon-scientist, and his research spans the spectrum from preclinical laboratory-based research to prospective clinical trials. The primary focus of his laboratory is on identifying key pathways that predict response and resistance to treatment in genitourinary malignancies. This includes work in prostate cancer to develop liquid biopsy approaches that can guide precision-based therapeutic strategies in real time, as well as ongoing research in renal cell carcinoma to identify genomic signatures for risk stratification.

Dr. Morgan is currently an Associate Professor of Urology and has been at the University of Michigan since 2012. In addition to his research pursuits, he is a busy clinician and surgeon offering advanced robotic, laparoscopic, and open surgical approaches for patients with genitourinary malignancies. He has substantial expertise in the

use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.

Beyond work, he loves his time enjoying the great town of Ann Arbor and beautiful state of Michigan with his wife, Wendy, and their two young boys. Whether camping in Petoskey, sitting on a beach in Grand Haven, or biking around the neighborhood in Ann Arbor, the Morgan family has quickly learned that life in the Midwest is hard to beat.



David S. Morris

Dr. Morris graduated Summa Cum Laude from Vanderbilt University and then earned his doctorate from Vanderbilt University School of Medicine. Dr. Morris completed his residency training at The University of Michigan in Ann Arbor, MI with a special research interest in genetics that predicts the aggressiveness of prostate and bladder cancers. He joined Urology Associates in Nashville after residency and starting work in the Clinical Research Department. Currently he is the PI director for the prostate trials program and a sub-investigator on our kidney and bladder programs. He co-directs the Advanced Therapeutics Center for our oncology patients. Since 2019 he has functioned as the President of the group. In the remainder of his clinical practice, he is a general urologist in the Nashville suburb of Gallatin. He enjoys time outside the office with his wife Betsy and daughters Avery and Lucy.



Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD

Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD is a urology and pelvic floor specialist, most

recently serving as Adjunct Professor of Surgery at the Perelman School of Medicine, University of Pennsylvania in Philadelphia. For more than 35 years, she has practiced as a nurse practitioner in urology, focusing on the evaluation, treatment, and conservative management of urinary incontinence, overactive bladder, and related pelvic floor disorders, including the use of catheters and other devices for bladder dysfunction.

Dr. Newman has led both industry- and NIH-funded research on urinary incontinence, overactive bladder, and urologic devices. An internationally recognized speaker, she has educated nurses and other healthcare professionals worldwide on conservative approaches to lower urinary tract dysfunction. She is the author of more than 100 peer-reviewed publications, numerous book chapters, and 17 books on urinary incontinence, urologic devices, and catheters—including textbooks for students, clinical guides for practitioners, and resources for patients and caregivers.



William P. Parker, MD

Dr. Parker is a board-certified urologic oncologist and Associate Professor of Urology at the University of Kansas Medical Center. His clinical and academic work focuses on improving the diagnosis, treatment, and quality of life for patients with prostate cancer. He has particular expertise in minimally invasive and image-guided techniques, including Retzius-sparing robotic prostatectomy.

Dr. Parker earned his undergraduate degree in Biochemistry and Molecular Biology from the University of Georgia and his medical degree from the Medical College of Georgia. He completed his urology residency at the University of Kansas Medical Center and a Society of Urologic Oncology (SUO) fellowship in Urologic Oncology at the Mayo Clinic in Rochester, Minnesota.

In addition to his clinical practice, Dr. Parker plays a key role in resident education and serves as a senior editor for oncology content in the American Urological Association (AUA) Core Curriculum. His research and teaching are centered on advancing prostate cancer care through innovation, education, and patient-centered outcomes.



Daniel P. Petrylak, MD

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. "Up until recently, bladder cancer had not seen any major advancement in more than 30 years," he says. "Studies are ongoing, but interim results are exciting so far."

At the Smilow Cancer Hospital, Dr. Petrylak's position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. "We offer the latest investigational drugs for these conditions, while providing the highest level of care," he says.

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Signal Transduction Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak's key goals is to continue to successfully translate basic research into clinical practice. "One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced

form of prostate cancer from phase I to III," he says. "We ran a trial which supported its approval for the most advanced form of prostate cancer."

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.



Scott B. Sellinger, MD

Dr. Sellinger has been a partner at Southeastern Urological Center, now a division of Advanced Urology Institute, since 1991. He received his BS degree in Chemistry from Syracuse University and attended Medical School at the University of Florida in Gainesville. He completed his Urology residency at the University of Florida and has lived in Tallahassee since 1991. He was President of the Capital Medical Society in 2003 and served

as President of the Florida Urological Society in 2005. In 2018, he served as President of the Southeastern Section of the American Urological Association (SESAUA). In 2019, he served as President of the American Association of Clinical Urologists (AACU).

In addition to his urology-specific work, Dr. Sellinger has developed a special interest in risk management and prevention of medical errors and has lectured extensively on this subject matter over the past several years. He is also interested in large group practice development and management. For several years, Dr. Sellinger has served on the board of Advanced Urology Institute (AUI) representing his care center in Tallahassee. In January 2021, he became the second President of AUI, now one of the largest independent urology practices in the United States. Dr. Sellinger currently chairs the Advanced Prostate Cancer (APC) Committee and oversees seven APC clinics within AUI. Since 2015, he has also served on the LUGPA Board of Directors, where he is currently Secretary. At LUGPA, he is proud to represent over 2300 urologists by working to preserve and advance the independent practice of urology.



LUGPA
Integrated Practices
Comprehensive Care

2026 LUGPA Meetings

The Urology Resident Summit and Job Fair

March 6-7, 2026
Marriott Philadelphia
Downtown
Philadelphia, PA

Fort Lauderdale Regional Meeting

March 27-28, 2026
The Westin
Fort Lauderdale
Beach Resort
Fort Lauderdale, FL

Ambulatory Surgery Center Academy

April 9-11, 2026
Lowes Chicago
O'Hare Hotel
Rosemont, IL


Las Vegas Regional Meeting and APP Forum

June 19-20, 2026
Caesars Palace
Las Vegas, NV

LUGPA 2026 Annual Meeting

November 5-7, 2026
Marriott Magnificent
Mile Hotel
Chicago, IL

Visit www.LUGPA.org/Events



LUGPA
Integrated Practices
Comprehensive Care

875 N. Michigan Avenue | Suite 3100 | Chicago, IL 60611 | www.lugpa.org

lugpa.org [f](#) [x](#) [in](#) [v](#)